X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (16) 16
oncology (16) 16
humans (13) 13
respiratory system (10) 10
chemotherapy (7) 7
aged (6) 6
aged, 80 and over (6) 6
female (6) 6
lung neoplasms - drug therapy (6) 6
male (6) 6
middle aged (6) 6
open-label (6) 6
adult (5) 5
cancer (5) 5
carcinoma, non-small-cell lung - drug therapy (5) 5
lung cancer (5) 5
lung neoplasms - pathology (5) 5
therapy (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
cell lung-cancer (4) 4
lung neoplasms - genetics (4) 4
protein kinase inhibitors - therapeutic use (4) 4
adjuvant chemotherapy (3) 3
antineoplastic agents - therapeutic use (3) 3
article (3) 3
carcinoma (3) 3
carcinoma, non-small-cell lung - genetics (3) 3
carcinoma, non-small-cell lung - pathology (3) 3
care and treatment (3) 3
colorectal cancer (3) 3
efficacy (3) 3
hematology, oncology and palliative medicine (3) 3
irinotecan (3) 3
mutation (3) 3
neoplasm staging (3) 3
neutropenia (3) 3
pharmacology & pharmacy (3) 3
pulmonary and respiratory medicine (3) 3
pulmonary/respiratory (3) 3
review (3) 3
surgery (3) 3
treatment outcome (3) 3
vinorelbine plus cisplatin (3) 3
1st-line treatment (2) 2
acquired-resistance (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
azd9291 (2) 2
brain metastases (2) 2
c-src (2) 2
cancer patients (2) 2
carcinoma, non-small-cell lung - metabolism (2) 2
clinical trials (2) 2
critical care medicine (2) 2
crizotinib (2) 2
drug approval (2) 2
drug therapy (2) 2
eml4-alk fusion gene (2) 2
erlotinib (2) 2
follow-up studies (2) 2
forthcoming 8th edition (2) 2
gefitinib (2) 2
immunoenzyme techniques (2) 2
immunotherapy (2) 2
inhibitor (2) 2
lung cancer, non-small cell (2) 2
lung neoplasms (2) 2
lung neoplasms - metabolism (2) 2
lung neoplasms - mortality (2) 2
lung neoplasms - therapy (2) 2
metabolism (2) 2
metastasis (2) 2
molecular targeted therapy (2) 2
mtor inhibitors (2) 2
phase-iii (2) 2
phase-iii trial (2) 2
previously treated patients (2) 2
prognosis (2) 2
protein kinase inhibitors - adverse effects (2) 2
quinazolines - therapeutic use (2) 2
receptor protein-tyrosine kinases - genetics (2) 2
receptor, epidermal growth factor - genetics (2) 2
research (2) 2
risk (2) 2
saracatinib (2) 2
small cell lung cancer (2) 2
sn-38 (2) 2
staging project proposals (2) 2
survival rate (2) 2
targeted therapy (2) 2
temsirolimus (2) 2
trial (2) 2
tyrosine kinase inhibitor (2) 2
tyrosine kinase inhibitors (2) 2
window of opportunity (2) 2
11 (1) 1
1a1 (1) 1
1st-line therapy (1) 1
38 (1) 1
38g (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | CNS RESPONSE | AZD9291 | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Carcinogenesis, ISSN 0974-6773, 01/2013, Volume 12, Issue 1, pp. 22 - 22
The iterative discovery in various malignancies during the past decades that a number of aberrant tumorigenic processes and signal transduction pathways are... 
non-small cell lung cancer | programmed cell death-1 receptor inhibitors | Drug resistance | protein kinase inhibitors | heat shock protein 90 inhibitors
Journal Article
Lung Cancer, ISSN 0169-5002, 2016, Volume 103, pp. 27 - 37
Journal Article
Investigational New Drugs, ISSN 0167-6997, 2/2015, Volume 33, Issue 1, pp. 225 - 232
Based on preclinical data demonstrating cytotoxic synergy between sorafenib and entinostat, a phase I study of this combination was conducted in patients with... 
Entinostat | Phase I | Medicine & Public Health | Histone deacetylase inhibitors | Sorafenib | Oncology | Pharmacology/Toxicology | VEGF inhibitors | APOPTOSIS | MS-275 | BORTEZOMIB | INDUCTION | CANCER | TRIAL | EPIGENETICS | MELANOMA | ONCOLOGY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | CARCINOMA | Niacinamide - analogs & derivatives | Apoptosis - drug effects | Humans | Middle Aged | Histone Deacetylase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Benzamides - administration & dosage | Pyridines - adverse effects | Phenylurea Compounds - adverse effects | Aged, 80 and over | Adult | Female | Benzamides - pharmacology | Benzamides - adverse effects | Pyridines - administration & dosage | Niacinamide - adverse effects | Treatment Outcome | Neoplasms - drug therapy | Niacinamide - administration & dosage | Phenylurea Compounds - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cell Line, Tumor | Histone Deacetylase Inhibitors - pharmacology | Aged | Phenylurea Compounds - pharmacology | Pyridines - pharmacology | Niacinamide - pharmacology | Histone Deacetylase Inhibitors - adverse effects | Chemotherapy, Combination | Research | Drug therapy | Tumors | Studies | Cytotoxicity | Inhibitor drugs | Vascular endothelial growth factor | Pharmaceutical sciences | Index Medicus
Journal Article
Cancer Research, ISSN 0008-5472, 08/2015, Volume 75, Issue 15 Supplement, pp. 5492 - 5492
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2018, Volume 36, Issue 3, pp. 276 - 282
Purpose No standard treatment exists for patients with cholangiocarcinoma for whom first-line gemcitabine-based therapy fails. Fibroblast growth factor... 
CRITERIA | ONCOLOGY | INHIBITOR | CANCER | INTRAHEPATIC CHOLANGIOCARCINOMAS | GENETIC ALTERATIONS | Index Medicus | ORIGINAL REPORTS
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2018, Volume 36, Issue 33, pp. 3290 - 3297
PurposeWe report CNS efficacy of osimertinib versus standard epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with... 
SURVIVAL | IMPACT | THERAPY | EFFICACY | ONCOLOGY | BRAIN METASTASES | ACQUIRED-RESISTANCE | AZD9291
Journal Article
World Journal of Surgical Oncology, ISSN 1477-7819, 05/2016, Volume 14, Issue 1, p. 139
Background: Anaplastic lymphoma kinase (ALK) gene rearrangement is detected in 3 % to 13 % of non-small cell lung carcinoma patients, and these patients... 
Crizotinib | Efficacy | Pulmonary adenocarcinoma | ALK gene rearrangement | SURGERY | EML4-ALK FUSION GENE |